Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Quoin Pharmaceuticals, Ltd. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
0
Research and development
3.32
0.05
0.24
1.56
2.67
3.31
3.6
9.8
Selling, general and administrative
0.99
1.51
1.43
4.5
6.58
6.07
5.93
6.49
Operating income
-7.05
-6.46
-4.35
Interest expense
1.12
0.43
0.05
1.09
Interest income
0.03
2.02
0.1
0.56
0.48
Other non-operating income
-0.43
-15.4
-0.12
0.69
0.57
0.49
Pre-tax income
-8.96
-15.8
Net income
-8.14
-1.56
-2.1
-21.5
-9.38
-8.69
-8.96
-15.8
EPS, basic
0.07
-0.52
-0.70
-0.01
EPS, diluted
0.07
-0.52
-0.70
-0.01
Shares, basic (weighted)
1,201
1,201
1,585
Shares, diluted (weighted)
1,201
1,201
1,585
Balance sheet
FY2017
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
3.96
5.63
0.32
7.48
2.86
2.4
3.62
3.82
Short-term investments
10.4
14.9
Receivables
0
0.01
Other current assets
0.72
0.52
0.59
0.87
1.26
Total current assets
8.24
5.38
0.47
8.2
13.4
11.3
14.9
20
Property, plant and equipment
0.39
0.37
0.38
Intangible assets
0.91
0.81
0.7
0.58
0.48
0.38
Total assets
8.76
6.17
1.38
9.36
14.5
12.2
15.7
20.4
Accounts payable
0.92
0.61
0.53
0.91
1.26
Accrued liabilities
0.96
1.69
1.18
1.31
1.53
2.54
Total current liabilities
1.18
1.05
0.93
4.58
3.53
3.58
4.18
5.55
Lease liabilities
0.2
0.12
Other non-current liabilities
3.52
2.92
2.32
1.72
Total liabilities
3.32
1.88
7.99
8.7
7.05
6.51
6.5
7.27
Paid-in capital
31.4
0
31.7
47.9
51.9
64.4
84.1
Retained earnings
-18.4
-29.2
-6.61
-28.1
-37.5
-46.2
-55.2
-71
Treasury stock
-2.93
-2.93
Other comprehensive income
28.1
37.5
46.2
55.2
-0
Shareholders' equity
-4.51
-6.61
0.66
7.41
5.66
9.2
13.1
Total equity
5.44
4.29
4.66
0.66
7.41
5.66
9.2
13.1
Total liabilities and equity
8.76
6.17
1.38
9.36
14.5
12.2
15.7
20.4
Shares outstanding
1,201
3,355
0.4
0.99
8.95
52.4
Cash flow statement
FY2017
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-8.14
-1.56
-2.1
-21.5
-9.38
-8.69
-8.96
-15.8
Stock-based compensation
0
0.76
1.09
1.26
1.15
Change in payables
0.05
0.28
1.33
Cash from operations
-5.13
-1.3
-1.34
-5.72
-8.48
-7.86
-7.86
-13.5
Capital expenditures
-0.08
-0.04
-0.1
Purchases of investments
-9.9
-18.1
-17.3
-12.3
Sales and maturities of investments
20.3
15.4
7.99
Cash from investing
2.91
-0.03
-0.13
-0.63
-10.1
2.19
-1.89
-4.28
Stock issued
4.15
6.48
2.86
11.6
18.6
Cash from financing
4.56
1.3
1.79
13.5
14
5.22
11
18
Exchange rate effect
-0.2
-0.33
0.39
Net change in cash
2.15
-0
0.32
7.16
-4.62
-0.46
1.22
0.19
Free cash flow
-5.2
-1.33
-1.44
Interest paid
0.39
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $6.43 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-474.6%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-155.9%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
42.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
21.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
29.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
12.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
71.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.76x
Current assets / current liabilities.
Quick ratio
1.63x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.63x
(Cash + short-term investments) / current liabilities.
Market cap + total debt - cash - short-term investments.
P/B
3.28x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.59x
Market cap / tangible book value, when positive.
Earnings yield
-144.5%
Net income / market cap (the inverse of P/E).
Was Quoin Pharmaceuticals, Ltd. profitable in fiscal 2025?
No. It reported a net loss of $15.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.